Washington
Q3 2026 · filed Oct 19Lobbying Q3 $30K 0.0% QoQ
YoY 0.0% vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
HCRHealth IssuesMMMMedicare/Medicaid
8 quarters Open in Washington ›
BDSX
BIODESIX INC$20.46 −0.80 (−3.76%)
Oct 27 4:00 PM ET · prev $21.26
Market cap
$252.6M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$40.00
+96% · range $35.00–41.00
Next earnings
Nov 2
in 6 days · EPS est. −$0.75
1 year
+207.7%
from $6.65 · Oct 27
30 days
−32.7%
from $30.42
52-week range
$5.46–30.60
−33% from high · low Jan 9
Avg volume 20D
87.5K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$932.7K
1 buyer · 5 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 5 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Nov 2, 2026
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- S Feb 10 5 insiders sell $57.7K at $10.08
- S Feb 23 5 insiders sell $42.5K at $12.78
- R May 4 Biodesix reported Q1 2026 revenue of $25.6M (+42% YoY) and EPS of -$…
- A Jun 25 Roth Capital initiates
- B Aug 10 to Aug 12 3 days of insider buys: $1.0M by 1 insider, avg $24.25
- X Aug 31 Short interest jumps 46.8% to 220.4K
- E Oct 19 FDA: American College of Chest Physicians Publishes New Framewo…
- R Oct 19 Biodesix announced that the American College of Chest Physicians (CH…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $1.0M at an average $24.25. 5 insiders sold $100.2K. Price is 16% below their cost.
- InstitutionsBULLISH
Q2 2026: 8 added (0 new), 3 trimmed or exited.
- AnalystsBULLISH
12 of 13 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.786 → −$0.750 over 90 days. 6 up, 1 down in 30 days.
- TrendDOWNTREND
23% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | DOUBLED | $2.1M |
| Walleye Capital LLC | DOUBLED | $1.7M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $1.5M |
| BlackRock, Inc. | ADD | $970.2K |
| BLAIR WILLIAM & CO/IL | ADD | $936.9K |
| VANGUARD FIDUCIARY TRUST CO | ADD | $901.1K |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $646.0K |
| MILLENNIUM MANAGEMENT LLC | TRIM | $324.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analysts 92% rate it Buy or better
12-month targets · 6 analysts
$20.46 $35.00 $40.00 $41.00
Price is below the lowest target. Median implies +96%.Targets as of Oct 27, 2026.
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Oct 13, 2026 | TD Cowen MAINTAIN | Buy |
| Sep 25, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 10, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Aug 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jun 25, 2026 | Roth Capital INITIATE | Buy |
| Jun 18, 2026 | Canaccord Genuity MAINTAIN | Buy |
Insider ledger
Form 4$1.0M
bought · 1 insider
$100.2K
sold · 5 insiders
−15.6%
vs their $24.25 cost
| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 30, 2026 | PATIENCE JOHN Director | EXERCISE | 1,360 sh |
| Aug 12, 2026 | SCHULER JACK W 10%+ Owner | BUY | $367.0K |
| Aug 11, 2026 | SCHULER JACK W 10%+ Owner | BUY | $328.9K |
| Aug 10, 2026 | SCHULER JACK W 10%+ Owner | BUY | $337.0K |
| Jun 30, 2026 | PATIENCE JOHN Director | EXERCISE | 1,361 sh |
| Mar 31, 2026 | PATIENCE JOHN Director | EXERCISE | 1,361 sh |
| Feb 23, 2026 | Hutton Scott President & CEO | SELL | $19.0K |
| Feb 23, 2026 | O'Kane Kieran Chief Commercial Officer | SELL | $6.8K |
Earnings setup
EstimatesNov 2
reports in 6 days
−$0.75
EPS estimate, this quarter
+5%
estimate change, 90 days
6↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
−$0.78690d
−$0.75060d
−$0.75030d
−$0.7507d
−$0.750Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.75 | -$0.80–-$0.70 | +0.0% | $27.6M |
| Next Q | -$0.43 | -$0.51–-$0.37 | +0.0% | $32.0M |
| Current FY | -$2.67 | -$2.79–-$2.56 | +0.0% | $112.0M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Press Aug 13, 2026 SEC Aug 12, 2026 SEC
Biodesix announced that the American College of Chest Physicians (CHEST) published a new framework for lung nodule…
Impact 6/10
Oct 19, 2026 FDA
Oct 19, 2026 Press American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and m
Biodesix announced a Digital Diagnostics initiative to build a multimodal lung diagnostic platform combining…
Impact 4/10
Sep 30, 2026 Insider
Aug 15, 2026 SEC PATIENCE JOHN acquired via exercise 1,360 shares
Director
Four institutional investors accumulated $2.9M in Biodesix (BDSX) during Q2 2026, led by Walleye Capital doubling its…
INST-CLUSTER — Impact 6/10
10% owner Jack Schuler made three open-market purchases of BDSX totaling $1.03M over three consecutive days (Aug…
INSIDER-BUY — Impact 6/10
Biodesix 10% owner Jack Schuler made two open-market purchases totaling $666K at ~$24/share, following the company's…
INSIDER-BUY — Impact 6/10
Aug 12, 2026 Insider
SCHULER JACK W bought 15,000 shares
10%+ Owner @ $24.47 ($367.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Oct 19, 2026
FDA
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse…
Oct 19, 2026
Contract
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk…
Sep 24, 2026
Press release
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise Biodesix-led…
Sep 14, 2026
Press release
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung…
Sep 3, 2026
Press release
Biodesix to Participate in Upcoming Investor Conferences
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that…
SecBot reports
7 filings · 3 press releases · 5 bullish · 0 bearish · 2 neutral- BULLISH PRESS RELEASEOct 19, 2026
Biodesix announced that the American College of Chest Physicians (CHEST) published a new framework…
Monitor for any subsequent announcements of new hospital system contracts or reimbursement expansions tied to the CHEST framework. The endorsement is a positive signal for adoption but lacks hard…
- NEUTRAL PRESS RELEASEOct 19, 2026
Biodesix announced a Digital Diagnostics initiative to build a multimodal lung diagnostic platform…
Monitor the RSNA 2026 presentation on December 3, 2026 for initial clinical performance data, which will be the first catalyst for this initiative. Also watch for updates on the STRATIFY study and…
- BULLISH INST-CLUSTERAug 15, 2026
Four institutional investors accumulated $2.9M in Biodesix (BDSX) during Q2 2026, led by Walleye…
The active-manager-led accumulation (Walleye Capital doubling) combined with insider buying and a strong Q2 beat suggests continued momentum. Monitor for further insider buying and Q3 2026 revenue…
- BULLISH INSIDER-BUYAug 13, 2026
10% owner Jack Schuler made three open-market purchases of BDSX totaling $1.03M over three…
The cluster of three consecutive open-market buys by a 10% owner immediately after a strong earnings beat is a bullish signal. Monitor for any follow-on purchases or a Form 13D amendment; the next…
All BDSX filing & press-release reports (10)
- PRESS-RELEASE reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- INST-CLUSTER reportAug 15, 2026
- INSIDER-BUY reportAug 13, 2026
- INSIDER-BUY reportAug 12, 2026
- 8-K reportAug 5, 2026
- EFFECT reportJun 1, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 20, 2026
- PRESS-RELEASE reportMar 20, 2026